ENTO - Entero Therapeutics, Inc.
Entero Therapeutics, Inc. Logo

ENTO - Entero Therapeutics, Inc.

https://www.enterothera.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida.

52W High
$2.95
52W Low
$0.84
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.89
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.10
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.27
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
7.30%
Institutions (25–75% balanced)
2.56%
Shares Outstanding
1,588,600
Float
1,482,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-11.97
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.24%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.3231
Previous
0.2624
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025